ArticleFrontiers in immunology2026
From blood to bowel: correlating serological markers with mucosal healing and inflammation in patients with inflammatory bowel disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD) is a systemic disease characterized by chronic inflammation of the gastrointestinal tract. Serological testing has the advantages of wide sources and easy detection. Objective: To explore the correlation between the serological markers and endoscopic mucosal healing and histological healing. We also explored the predictive value of individual and combined detection on the disease activity of ulcerative colitis (UC) and Crohn's disease (CD) and provide reference for clinical non-invasive evaluation. Methods: We retrospectively analyzed 267 IBD patients treated at our hospital from May 2020 to June 2024. Patients were classified based on endoscopic, pathological, or imaging results into UC (141 patients) and CD (126 patients). UC patients were further divided into mucosal healing (32 cases, IMES ≤ 1), mild (41 cases, 3 ≤ IMES ≤ 5), moderate (49 cases, 6 ≤ IMES ≤ 10), and severe (19 cases, 11 ≤ IMES ≤ 12) phases by the Improved Mayo Endoscopic Score (IMES). CD patients were categorized by the Crohn's Disease Activity Index (CDAI). According to the Geboes score, patients were divided into a histological healing group (n=63) and a histological activity group (n=204). Pearson analysis examined correlations and ROC analysis assessed their predictive value. Results: In severe cases, ALB and PA were lower, and CRP, ESR, NLR, and PLR were higher than in moderate cases (P<0.05). The serum ALB and PA levels in the histological activity group were lower, but CRP, ESR, NLR, and PLR were higher than the histological healing group (all P<0.05). Pearson analysis revealed negative correlations between IMES/CDAI scores and ALB/PA levels, and positive correlations with CRP, ESR, NLR, and PLR levels (P<0.05). The combined detection of serological indicators for predicting UC inflammatory activity had an AUC of 0.930, with 88.89% sensitivity and 89.47% specificity, outperforming individual indicators (Z-values all P<0.05). For CD, the combined AUC was 0.906, with 86.75% sensitivity and 85.71% specificity, again surpassing single indicators (Z-values all P<0.05). Conclusion: Differences in serum ALB, PA, CRP, ESR, NLR, PLR were correlated with mucosal healing and inflammation in IBD patients. Combined detection offers clinical value in predicting disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.